Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biotech Hedge Fund Deerfield Management’s Top Stock Picks

Next in line is Allergan, Inc. (NYSE:AGN), one of the most widely discussed healthcare companies throughout 2014. The company became a potential takeover target by activist investor Bill Ackman of Pershing Square, who planned to purchase the pharmaceutical company together with Valeant Pharmaceuticals Intl Inc (NYSE:VRX). As Allergan, Inc. (NYSE:AGN) has been fighting the offer, its stock has been growing as investors were betting on Mr. Ackman winning the proxy fight with the company. The story took another step after another pharmaceutical company Actavis plc (NYSE:ACT) stepped in with a higher bid. All in all, the bets of activists have paid off and even better than expected, we can say. Meanwhile, many large investors have been bullish on Allergan, the company quickly becoming one of the most popular healthcare stocks. Deerfield initiated a stake in Allergan, Inc. (NYSE:AGN) in the middle of 2013, and throughout 2014 it has been constantly increasing the position. At the end of last year, the hedge fund held 606,600 shares of the company, valued at $128.96 million.

Allergan, Inc. (NYSE:AGN)

Deerfield’s stake in French-based Flamel Technologies S.A. (ADR) (NASDAQ:FLML) remained unchanged over the quarter at 5.26 million shares worth $90.08 million. The stock of the biopharmaceutical company gained 20% in the last quarter of 2014, but since the beginning of the year it fell by 9%. During the fourth quarter, Flamel Technologies S.A. (ADR) (NASDAQ:FLML) has attracted more interest from investors as the number of funds holding the stock increased to 27 which held around $284.33 million worth of the company’s stock, versus 18 funds holding $223.26 million of stock in the previous quarter. Broadfin Capital is also a shareholder of Flamel Technologies S.A. (ADR) (NASDAQ:FLML), disclosing ownership of 5.15 million shares in its last 13F filing.

And the last but not least is Avalanche Biotechnologies Inc (NASDAQ:AAVL), another biotech stock. Deerfield cut its position by 22% to 1.61 million shares, valued at $87.19 million. It seems like it was the right call, as Avalanche Biotechnologies Inc (NASDAQ:AAVL)’s stock lost around 33% since the beginning of the year. Mr. Flynn added the company to his fund’s equity portfolio during the third quarter and saw the stock jump by over 50% in the last three months of 2014. On the other hand, Venrock Healtchare Capital Partners, a fund specialized in biotech companies, initiated a $73.08 million position in Avalanche Biotechnologies Inc (NASDAQ:AAVL) during the fourth quarter of 2014 that contained 1.38 million shares.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.